Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

LAGOON : A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungSmall Cell Lung Cancer

Trial Overview Read MoreRead more

This phase III study is comparing how safe and effective an alkylating drug (lurbinectedin) is alone, or when combined with chemotherapy (irinotecan), compared to chemotherapy alone (irinotecan or topotecan) in people with relapsed small-cell lung cancer.
 

This trial is treating patients with relapsed small cell lung cancer.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Commercial Sponsor

PharmaMar

Summary

Eligible participants will be randomly allocated to one of three treatment arms. In Arm 1 (Experimental), participants will receive Lurbinectedin alone, which will be administered intravenously at a dose of 3.2 mg/m² on Day 1 of every 3-week cycle. In Arm 2 (Experimental), participants will receive Lurbinectedin plus Irinotecan. Lurbinectedin will be administered intravenously at a dose of 2.0 mg/m² on Day 1 of every 3 week cycle. Irinotecan will be administered intravenously at a dose of 75 mg/m² On Days 1 and 8 of every 2 week cycle. In Arm 3 (Active Comparator), participants will receive the Investigator's choice prior to randomisation of either Irinotecan or Topotecan. Irinotecan will be administered intravenously at a dose of 350 mg/m² on Day 1 of every 3 week cycle. Topotecan will be administered either orally at a dose of 2.3 mg/m² or intravenously at a dose of 1.5 mg/m² on Days 1-5 of every 3 week cycle.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital Medical Oncology
Box Hill
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next